Gut Barrier Testing

The article presents zonulin antibody testing as designed to avoid cross-reactivity and support blood spot collection. The article argues that zonulin protein testing has limitations that reduce clinical utility. Secretory IgA elevation is presented as indicating acute or early mucosal injury. IgG and C3D findings are described as reflecting sustained inflammation over time. The article identifies objective biomarker data as a prerequisite for accurate diagnosis and treatment sequencing. Technically negative results close to the cutoff line should be treated as clinically positive, according to the article. Gut function is said to often heal before tight-junction structure, creating a need for retesting beyond symptom resolution. The gut barrier panel is designed to distinguish leaky gut, food sensitivity alone, or both. The panel measures Candida, zonulin antibody, occludin, and LPS biomarkers.